February 26, 2026

Argenx Reports Positive Phase 3 VYVGART Data in Ocular Myasthenia Gravis – TipRanks

February 20, 2026

Research identifies a distinct immune signature in treatment-resistant Myasthenia Gravis – The University of Manchester

February 19, 2026

Euro Roundup: EMA seeks feedback on plans to draft myasthenia gravis clinical trial guideline – Regulatory Affairs Professionals Society | RAPS

February 17, 2026

Worse Cardiac Surgery Outcomes Seen in Patients With Myasthenia Gravis – AJMC

February 14, 2026

Disease Severity in MuSK Myasthenia Gravis Could Correlate to Antibody Levels – AJMC